Baird Maintains Certara(CERT.US) With Hold Rating, Maintains Target Price $13
Certara Hold Rating Maintained Amid Mixed Performance and Regulatory Concerns
Certara Is Maintained at Equal-Weight by Barclays
Certara Analyst Ratings
Barclays Maintains Certara(CERT.US) With Hold Rating, Cuts Target Price to $12
JMP Securities Maintains Certara(CERT.US) With Hold Rating
JMP Securities Sticks to Their Hold Rating for Certara (CERT)
Baird Maintains Certara(CERT.US) With Hold Rating, Cuts Target Price to $13
Certara Analyst Ratings
Baird Maintains Neutral on Certara, Lowers Price Target to $13
Barclays Maintains Certara(CERT.US) With Hold Rating, Maintains Target Price $14
Certara Is Maintained at Equal-Weight by Barclays
Certara Analyst Ratings
Barclays Maintains Certara(CERT.US) With Hold Rating, Cuts Target Price to $14
Analysts Offer Insights on Healthcare Companies: Certara (CERT) and CVRx (CVRX)
Certara Analyst Ratings
UBS Upgrades Certara(CERT.US) to Buy Rating, Maintains Target Price $16
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Morgan Stanley Lowers Price Target on Certara to $16 From $21, Keeps Equalweight Rating
Certara's Mixed Financial Performance Leads to Hold Rating Amid Market Fluctuations